Effects of Epitranscriptomic RNA Modifications on the Catalytic Activity of the SARS‐CoV‐2 Replication Complex
SARS‐CoV‐2 causes individualized symptoms. Many reasons have been given. We propose that an individual's epitranscriptomic system could be responsible as well. The viral RNA genome can be subject to epitranscriptomic modifications, which can be different for different individuals, and thus epit...
Saved in:
Published in | Chembiochem : a European journal of chemical biology Vol. 24; no. 8; pp. e202300095 - n/a |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Germany
Wiley Subscription Services, Inc
17.04.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | SARS‐CoV‐2 causes individualized symptoms. Many reasons have been given. We propose that an individual's epitranscriptomic system could be responsible as well. The viral RNA genome can be subject to epitranscriptomic modifications, which can be different for different individuals, and thus epitranscriptomics can affect many events including RNA replication differently. In this context, we studied the effects of modifications including pseudouridine (Ψ), 5‐methylcytosine (m5C), N6‐methyladenosine (m6A), N1‐methyladenosine (m1A) and N3‐methylcytosine (m3C) on the activity of SARS‐CoV‐2 replication complex (SC2RC). We found that Ψ, m5C, m6A and m3C had little effect, whereas m1A inhibited the enzyme. Both m1A and m3C disrupt canonical base pairing, but they had different effects. The fact that m1A inhibits SC2RC implies that the modification can be difficult to detect. This fact also implies that individuals with upregulated m1A including cancer, obesity and diabetes patients might have milder symptoms. However, this contradicts clinical observations. Relevant discussions are provided.
The RNA modifications Ψ, m5C and m6A have little effect on the catalytic activity of SARS‐CoV‐2 RdRp. However, although both m3C and m1A disrupt canonical base pairing, m3C can be read through by the RdRp readily, while m1A severely inhibits it. |
---|---|
AbstractList | SARS‐CoV‐2 causes individualized symptoms. Many reasons have been given. We propose that an individual's epitranscriptomic system could be responsible as well. The viral RNA genome can be subject to epitranscriptomic modifications, which can be different for different individuals, and thus epitranscriptomics can affect many events including RNA replication differently. In this context, we studied the effects of modifications including pseudouridine (Ψ), 5‐methylcytosine (m5C), N6‐methyladenosine (m6A), N1‐methyladenosine (m1A) and N3‐methylcytosine (m3C) on the activity of SARS‐CoV‐2 replication complex (SC2RC). We found that Ψ, m5C, m6A and m3C had little effect, whereas m1A inhibited the enzyme. Both m1A and m3C disrupt canonical base pairing, but they had different effects. The fact that m1A inhibits SC2RC implies that the modification can be difficult to detect. This fact also implies that individuals with upregulated m1A including cancer, obesity and diabetes patients might have milder symptoms. However, this contradicts clinical observations. Relevant discussions are provided. SARS‐CoV‐2 causes individualized symptoms. Many reasons have been given. We propose that an individual's epitranscriptomic system could be responsible as well. The viral RNA genome can be subject to epitranscriptomic modifications, which can be different for different individuals, and thus epitranscriptomics can affect many events including RNA replication differently. In this context, we studied the effects of modifications including pseudouridine (Ψ), 5‐methylcytosine (m5C), N6‐methyladenosine (m6A), N1‐methyladenosine (m1A) and N3‐methylcytosine (m3C) on the activity of SARS‐CoV‐2 replication complex (SC2RC). We found that Ψ, m5C, m6A and m3C had little effect, whereas m1A inhibited the enzyme. Both m1A and m3C disrupt canonical base pairing, but they had different effects. The fact that m1A inhibits SC2RC implies that the modification can be difficult to detect. This fact also implies that individuals with upregulated m1A including cancer, obesity and diabetes patients might have milder symptoms. However, this contradicts clinical observations. Relevant discussions are provided. The RNA modifications Ψ, m5C and m6A have little effect on the catalytic activity of SARS‐CoV‐2 RdRp. However, although both m3C and m1A disrupt canonical base pairing, m3C can be read through by the RdRp readily, while m1A severely inhibits it. SARS‐CoV‐2 causes individualized symptoms. Many reasons have been given. We propose that an individual's epitranscriptomic system could be responsible as well. The viral RNA genome can be subject to epitranscriptomic modifications, which can be different for different individuals, and thus epitranscriptomics can affect many events including RNA replication differently. In this context, we studied the effects of modifications including pseudouridine (Ψ), 5‐methylcytosine (m 5 C), N 6‐methyladenosine (m 6 A), N 1‐methyladenosine (m 1 A) and N 3‐methylcytosine (m 3 C) on the activity of SARS‐CoV‐2 replication complex (SC2RC). We found that Ψ, m 5 C, m 6 A and m 3 C had little effect, whereas m 1 A inhibited the enzyme. Both m 1 A and m 3 C disrupt canonical base pairing, but they had different effects. The fact that m 1 A inhibits SC2RC implies that the modification can be difficult to detect. This fact also implies that individuals with upregulated m 1 A including cancer, obesity and diabetes patients might have milder symptoms. However, this contradicts clinical observations. Relevant discussions are provided. SARS-CoV-2 causes individualized symptoms. Many reasons have been given. We propose that an individual’s epitranscriptomic system could be responsible as well. The viral RNA genome can be subject to epitranscriptomic modifications, the modifications can be different for different individuals, and thus epitranscriptomics can affect many events including RNA replication differently. In this context, we studied the effects of modifications including pseudouridine (Ψ), 5-methylcytosine (m 5 C), N 6 -methyladenosine (m 6 A), N 1 -methyladenosine (m 1 A) and N 3 -methylcytosine (m 3 C) on the activity of SARS-CoV-2 replication complex (SC2RC). We found that Ψ, m 5 C, m 6 A and m 3 C had little effects, while m 1 A inhibited the enzyme. Both m 1 A and m 3 C disrupt canonical base-pairing, but they had different effects. The fact that m 1 A inhibits SC2RC implies that the modification can be difficult to detect. The fact also implies that individuals with upregulated m 1 A including cancer, obesity and diabetes patients may have milder symptoms. However, this contradicts clinical observations. Relevant discussions are provided. SARS-CoV-2 causes individualized symptoms. Many reasons have been given. We propose that an individual's epitranscriptomic system could be responsible as well. The viral RNA genome can be subject to epitranscriptomic modifications, which can be different for different individuals, and thus epitranscriptomics can affect many events including RNA replication differently. In this context, we studied the effects of modifications including pseudouridine (Ψ), 5-methylcytosine (m5 C), N6-methyladenosine (m6 A), N1-methyladenosine (m1 A) and N3-methylcytosine (m3 C) on the activity of SARS-CoV-2 replication complex (SC2RC). We found that Ψ, m5 C, m6 A and m3 C had little effect, whereas m1 A inhibited the enzyme. Both m1 A and m3 C disrupt canonical base pairing, but they had different effects. The fact that m1 A inhibits SC2RC implies that the modification can be difficult to detect. This fact also implies that individuals with upregulated m1 A including cancer, obesity and diabetes patients might have milder symptoms. However, this contradicts clinical observations. Relevant discussions are provided.SARS-CoV-2 causes individualized symptoms. Many reasons have been given. We propose that an individual's epitranscriptomic system could be responsible as well. The viral RNA genome can be subject to epitranscriptomic modifications, which can be different for different individuals, and thus epitranscriptomics can affect many events including RNA replication differently. In this context, we studied the effects of modifications including pseudouridine (Ψ), 5-methylcytosine (m5 C), N6-methyladenosine (m6 A), N1-methyladenosine (m1 A) and N3-methylcytosine (m3 C) on the activity of SARS-CoV-2 replication complex (SC2RC). We found that Ψ, m5 C, m6 A and m3 C had little effect, whereas m1 A inhibited the enzyme. Both m1 A and m3 C disrupt canonical base pairing, but they had different effects. The fact that m1 A inhibits SC2RC implies that the modification can be difficult to detect. This fact also implies that individuals with upregulated m1 A including cancer, obesity and diabetes patients might have milder symptoms. However, this contradicts clinical observations. Relevant discussions are provided. SARS-CoV-2 causes individualized symptoms. Many reasons have been given. We propose that an individual's epitranscriptomic system could be responsible as well. The viral RNA genome can be subject to epitranscriptomic modifications, which can be different for different individuals, and thus epitranscriptomics can affect many events including RNA replication differently. In this context, we studied the effects of modifications including pseudouridine (Ψ), 5-methylcytosine (m C), N6-methyladenosine (m A), N1-methyladenosine (m A) and N3-methylcytosine (m C) on the activity of SARS-CoV-2 replication complex (SC2RC). We found that Ψ, m C, m A and m C had little effect, whereas m A inhibited the enzyme. Both m A and m C disrupt canonical base pairing, but they had different effects. The fact that m A inhibits SC2RC implies that the modification can be difficult to detect. This fact also implies that individuals with upregulated m A including cancer, obesity and diabetes patients might have milder symptoms. However, this contradicts clinical observations. Relevant discussions are provided. |
Author | Apostle, Alexander Burke, Emma Fang, Shiyue Yuan, Yinan Chillar, Komal Arneson, Reed Eriyagama, Adikari M. D. N. Yin, Yipeng |
AuthorAffiliation | a Department of Chemistry and Health Research Institute, Michigan Technological University, 1400 Townsend Drive, Houghton, MI 49931, USA b College of Forest Resources and Environmental Science, Michigan Technological University, 1400 Townsend Drive, Houghton, MI 49931, USA |
AuthorAffiliation_xml | – name: b College of Forest Resources and Environmental Science, Michigan Technological University, 1400 Townsend Drive, Houghton, MI 49931, USA – name: a Department of Chemistry and Health Research Institute, Michigan Technological University, 1400 Townsend Drive, Houghton, MI 49931, USA |
Author_xml | – sequence: 1 givenname: Alexander surname: Apostle fullname: Apostle, Alexander organization: Michigan Technological University – sequence: 2 givenname: Yipeng surname: Yin fullname: Yin, Yipeng organization: Michigan Technological University – sequence: 3 givenname: Komal surname: Chillar fullname: Chillar, Komal organization: Michigan Technological University – sequence: 4 givenname: Adikari M. D. N. surname: Eriyagama fullname: Eriyagama, Adikari M. D. N. organization: Michigan Technological University – sequence: 5 givenname: Reed surname: Arneson fullname: Arneson, Reed organization: Michigan Technological University – sequence: 6 givenname: Emma surname: Burke fullname: Burke, Emma organization: Michigan Technological University – sequence: 7 givenname: Shiyue orcidid: 0000-0002-6523-7557 surname: Fang fullname: Fang, Shiyue email: shifang@mtu.edu organization: Michigan Technological University – sequence: 8 givenname: Yinan surname: Yuan fullname: Yuan, Yinan email: yinyuan@mtu.edu organization: Michigan Technological University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36752976$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkctu1DAUhi1URC-wZYkisWEzg2-5eIWGaAqVCkhTYGs5zgl1ldip7SnMro_AM_IkOJ1hgEqIjW3pfP9_zvF_jA6ss4DQU4LnBGP6UjdGzymmDGMs8gfoiHAmZmXB2MHuzSktD9FxCFcTUjDyCB2yosypKIsj5JddBzqGzHXZcjTRKxu0N2N0g9HZ6v0ie-da0xmtonE2YTaLl5DVKqp-ExOy0NHcmLiZDKbKxWJ18eP2e-0-p5NmKxj7nTir3TD28O0xetipPsCT3X2CPp0uP9ZvZ-cf3pzVi_OZ5oXIZ01TVRqKTnBVcdywpgENVDWYVpiWXdtQXAgADJxwLXJCu0IohgnLW1qSlrIT9GrrO66bAVoNNm3Xy9GbQfmNdMrIvyvWXMov7kYSTCgRRCSHFzsH767XEKIcTNDQ98qCWwdJy5JzIfAd-vweeuXW3qb9ZJqXVBUTBU7Usz9H2s_yK48EzLeA9i4ED90eIVhOgcspcLkPPAn4PYE28e6700qm_7dMbGVfTQ-b_zSR9euz-rf2JzNSwe0 |
CitedBy_id | crossref_primary_10_3389_fimmu_2023_1286820 crossref_primary_10_3390_microorganisms12112373 crossref_primary_10_1261_rna_079991_124 crossref_primary_10_1134_S0006297924120149 |
Cites_doi | 10.1038/s41467-021-24824-z 10.1016/j.diabres.2020.108347 10.1016/j.tranon.2019.06.007 10.1007/s00432-018-2796-0 10.3390/genes13050910 10.1016/0006-291X(75)90361-7 10.1038/s41421-020-00241-2 10.1021/acsomega.7b01482 10.1093/nar/30.5.1124 10.1016/j.annonc.2020.03.296 10.1021/acs.joc.9b01527 10.1016/j.biomaterials.2016.09.006 10.1128/mBio.02131-20 10.7717/peerj.10181 10.1038/s41586-020-2008-3 10.1038/s41421-021-00318-6 10.3389/fmolb.2021.692130 10.1016/j.ctrv.2020.102041 10.1016/j.jdiacomp.2020.107817 10.1186/s12920-020-00839-1 10.1093/nar/gky341 10.1126/sciadv.abd2605 10.1016/S1473-3099(22)00143-8 10.3390/v13112108 10.1038/nature24456 10.1128/mBio.01067-21 10.1007/s00706-022-02896-x 10.1038/sj.bjc.6606012 10.3762/bjoc.15.108 10.1038/s41467-019-12504-y 10.1038/s41590-021-01030-z 10.1038/nature16998 10.1111/cob.12403 10.3390/vaccines8040700 10.1073/pnas.1323705111 10.1186/s12876-022-02160-w 10.1021/acschembio.0c00735 10.1038/s41467-020-18463-z 10.1016/j.molcel.2017.10.019 10.3389/fendo.2018.00396 10.1126/science.abc1560 10.1038/cr.2014.162 10.12659/MSM.913556 10.1038/s41592-019-0550-4 10.1038/s41588-021-00903-1 10.1016/j.cell.2020.04.011 10.1002/gepi.22421 10.1186/s40246-021-00306-7 |
ContentType | Journal Article |
Copyright | 2023 Wiley‐VCH GmbH 2023 Wiley-VCH GmbH. |
Copyright_xml | – notice: 2023 Wiley‐VCH GmbH – notice: 2023 Wiley-VCH GmbH. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7QO 7TM 7U9 8FD C1K FR3 H94 K9. M7N P64 7X8 5PM |
DOI | 10.1002/cbic.202300095 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Biotechnology Research Abstracts Technology Research Database Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Virology and AIDS Abstracts CrossRef MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Chemistry |
EISSN | 1439-7633 |
EndPage | n/a |
ExternalDocumentID | PMC10121919 36752976 10_1002_cbic_202300095 CBIC202300095 |
Genre | article Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIH funderid: GM109288 – fundername: NSF equipment grants funderid: 1048655; 9512455; 1531454 – fundername: Robert and Kathleen Lane Endowed Fellowship – fundername: NSF funderid: 1954041 – fundername: NIGMS NIH HHS grantid: R15 GM109288 |
GroupedDBID | --- -DZ -~X 05W 0R~ 1L6 1OC 29B 33P 3WU 4.4 4ZD 50Y 5GY 5VS 66C 6J9 6P2 77Q 8-0 8-1 8UM A00 AAESR AAHHS AAHQN AAIHA AAMNL AANLZ AAXRX AAYCA AAZKR ABCUV ABIJN ABJNI ABLJU ACAHQ ACCFJ ACCZN ACGFS ACIWK ACPOU ACPRK ACXBN ACXQS ADBBV ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFRAH AFWVQ AFZJQ AHBTC AHMBA AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMYDB AZVAB BDRZF BFHJK BMXJE BRXPI CS3 DCZOG DPXWK DR2 DRFUL DRSTM DU5 EBD EBS EMOBN F5P G-S GNP HBH HGLYW HHY HHZ HZ~ IH2 IX1 JPC KQQ LATKE LAW LEEKS LITHE LOXES LUTES LYRES MEWTI MXFUL MXSTM MY~ NNB O9- OIG P2P P2W P4E PQQKQ R.K ROL RWI RX1 SUPJJ SV3 V2E W99 WBKPD WH7 WJL WOHZO WXSBR WYJ XPP XV2 Y6R YZZ ZZTAW ~KM ~S- AAYXX AEYWJ AGHNM AGYGG CITATION CGR CUY CVF ECM EIF NPM 7QL 7QO 7TM 7U9 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY C1K FR3 H94 K9. M7N P64 7X8 5PM |
ID | FETCH-LOGICAL-c4695-bb88ce6f94a840b3bbece2ab028027fdb2069ee0e414c9512f69a30135d271d23 |
IEDL.DBID | DR2 |
ISSN | 1439-4227 1439-7633 |
IngestDate | Thu Aug 21 18:34:11 EDT 2025 Thu Jul 10 18:22:16 EDT 2025 Fri Jul 25 12:16:32 EDT 2025 Wed Feb 19 02:09:57 EST 2025 Thu Apr 24 22:50:22 EDT 2025 Tue Jul 01 04:35:24 EDT 2025 Wed Jan 22 16:23:35 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Keywords | COVID-19 RNA modification SARS-CoV-2 RNA-dependent RNA polymerase epitranscriptomics |
Language | English |
License | 2023 Wiley-VCH GmbH. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4695-bb88ce6f94a840b3bbece2ab028027fdb2069ee0e414c9512f69a30135d271d23 |
Notes | . A previous version of the manuscript has been deposited on a preprint server https://doi.org/10.1101/10.26434/chemrxiv‐2022‐rsm6s‐v2 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-6523-7557 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/10121919 |
PMID | 36752976 |
PQID | 2801883960 |
PQPubID | 986344 |
PageCount | 7 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10121919 proquest_miscellaneous_2774499019 proquest_journals_2801883960 pubmed_primary_36752976 crossref_primary_10_1002_cbic_202300095 crossref_citationtrail_10_1002_cbic_202300095 wiley_primary_10_1002_cbic_202300095_CBIC202300095 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | April 17, 2023 |
PublicationDateYYYYMMDD | 2023-04-17 |
PublicationDate_xml | – month: 04 year: 2023 text: April 17, 2023 day: 17 |
PublicationDecade | 2020 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany – name: Weinheim |
PublicationTitle | Chembiochem : a European journal of chemical biology |
PublicationTitleAlternate | Chembiochem |
PublicationYear | 2023 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2021; 9 2021; 8 2021; 7 2022; 153 2017; 2 2021; 45 2002; 30 2016; 109 2019; 10 2020; 181 2019; 12 2017; 68 2019; 15 2022; 23 2020; 368 2019; 16 2020; 13 2020; 166 2020; 11 2022; 22 2020; 10 2017; 551 2014; 111 2019; 145 2018; 46 2020; 8 2021; 13 2021; 35 2011; 104 2021; 16 2018; 9 2021; 15 2015; 25 2021; 53 2021; 12 2019; 84 2020; 31 2022 2020 2019; 25 2022; 13 2016; 530 2020; 579 1975; 64 2022; 10 2020; 88 e_1_2_9_52_2 e_1_2_9_50_2 e_1_2_9_10_2 e_1_2_9_56_2 e_1_2_9_35_1 e_1_2_9_12_2 e_1_2_9_31_2 e_1_2_9_33_1 e_1_2_9_54_1 Ballow M. (e_1_2_9_2_1) 2021; 9 Apostle A. (e_1_2_9_17_2) 2022 Vacca D. (e_1_2_9_30_2) 2020 e_1_2_9_14_2 e_1_2_9_39_1 e_1_2_9_16_2 e_1_2_9_37_1 e_1_2_9_58_1 e_1_2_9_18_1 e_1_2_9_41_1 e_1_2_9_64_1 e_1_2_9_62_2 e_1_2_9_20_2 e_1_2_9_45_2 e_1_2_9_22_2 e_1_2_9_43_2 e_1_2_9_8_1 e_1_2_9_6_2 e_1_2_9_4_2 e_1_2_9_60_1 Taiaroa G. (e_1_2_9_29_2) 2020 e_1_2_9_26_1 e_1_2_9_24_2 e_1_2_9_49_2 e_1_2_9_47_1 e_1_2_9_51_2 e_1_2_9_53_1 e_1_2_9_34_1 e_1_2_9_55_2 e_1_2_9_13_1 e_1_2_9_11_2 e_1_2_9_32_2 Miladi M. (e_1_2_9_28_2) 2020 e_1_2_9_38_1 e_1_2_9_36_1 e_1_2_9_59_1 e_1_2_9_15_2 e_1_2_9_57_2 e_1_2_9_19_1 e_1_2_9_63_1 e_1_2_9_61_2 e_1_2_9_40_1 e_1_2_9_21_2 e_1_2_9_44_2 e_1_2_9_42_2 e_1_2_9_23_1 e_1_2_9_7_1 e_1_2_9_5_2 e_1_2_9_3_1 Spratt A. N. (e_1_2_9_1_1) 2022; 10 e_1_2_9_9_2 e_1_2_9_25_2 e_1_2_9_48_2 e_1_2_9_46_2 e_1_2_9_27_1 |
References_xml | – volume: 12 year: 2021 publication-title: mBio – volume: 31 start-page: 894 year: 2020 end-page: 901 publication-title: Ann. Oncol. – volume: 166 year: 2020 publication-title: Diabetes Res. Clin. Pract. – year: 2020 publication-title: bioRxiv – volume: 13 start-page: 910 year: 2022 publication-title: Genes – volume: 2 start-page: 8205 year: 2017 end-page: 8212 publication-title: ACS Omega – volume: 111 start-page: E3900 year: 2014 end-page: E3909 publication-title: Proc. Natl. Acad. Sci. USA – volume: 25 start-page: 3 year: 2015 end-page: 4 publication-title: Cell Res. – volume: 88 year: 2020 publication-title: Cancer Treat. Rev. – volume: 23 start-page: 159 year: 2022 end-page: 164 publication-title: Nat. Immunol. – volume: 13 start-page: 2108 year: 2021 publication-title: Viruses – volume: 530 start-page: 441 year: 2016 end-page: 446 publication-title: Nature – volume: 8 year: 2021 publication-title: Front. Mol. Biosci. – volume: 10 start-page: 4595 year: 2019 publication-title: Nat. Commun. – volume: 11 start-page: 4682 year: 2020 publication-title: Nat. Commun. – volume: 7 start-page: 76 year: 2021 publication-title: Cell Discovery – volume: 25 start-page: 3894 year: 2019 end-page: 3901 publication-title: Med. Sci. Monit. – volume: 145 start-page: 19 year: 2019 end-page: 29 publication-title: J. Cancer Res. Clin. – volume: 15 start-page: 10 year: 2021 publication-title: Hum. Genomics – volume: 579 start-page: 265 year: 2020 end-page: 269 publication-title: Nature – volume: 104 start-page: 700 year: 2011 end-page: 706 publication-title: Br. J. Cancer – volume: 9 start-page: 1442 year: 2021 end-page: 1448 publication-title: J. Allergy Clin. Immunol. – volume: 84 start-page: 13374 year: 2019 end-page: 13383 publication-title: J. Org. Chem. – volume: 22 start-page: 93 year: 2022 publication-title: BMC Gastroenterol. – volume: 16 start-page: 1281 year: 2019 end-page: 1288 publication-title: Nat. Methods – volume: 12 start-page: 1323 year: 2019 end-page: 1333 publication-title: Transl. Oncol. – volume: 46 start-page: 5753 year: 2018 end-page: 5763 publication-title: Nucleic Acids Res. – volume: 7 start-page: 7 year: 2021 publication-title: Cell Discovery – volume: 16 start-page: 76 year: 2021 end-page: 85 publication-title: ACS Chem. Biol. – volume: 15 start-page: 1116 year: 2019 end-page: 1128 publication-title: Beilstein J. Org. Chem. – volume: 153 start-page: 285 year: 2022 end-page: 291 publication-title: Monatsh. Chem. – volume: 64 start-page: 581 year: 1975 end-page: 586 publication-title: Biochem. Biophys. Res. Commun. – volume: 68 start-page: 993 year: 2017 end-page: 1005 publication-title: Mol. Cell – volume: 10 year: 2022 publication-title: Biomedicine – volume: 8 start-page: 700 year: 2020 publication-title: Vaccine – volume: 22 start-page: 781 year: 2022 end-page: 790 publication-title: Lancet Infect. Dis. – volume: 45 start-page: 685 year: 2021 end-page: 693 publication-title: Genet. Epidemiol. – volume: 13 start-page: 186 year: 2020 publication-title: BMC Med. Genomics – volume: 53 start-page: 1113 year: 2021 end-page: 1116 publication-title: Nat. Genet. – volume: 368 start-page: 1499 year: 2020 end-page: 1504 publication-title: Science – volume: 11 start-page: e02131 year: 2020 end-page: 02120 publication-title: mBio – volume: 30 start-page: 1124 year: 2002 end-page: 1131 publication-title: Nucleic Acids Res. – volume: 9 start-page: 396 year: 2018 publication-title: Front. Endocrinol. – year: 2022 publication-title: J. Mass Spectrom. – volume: 7 year: 2021 publication-title: Sci. Adv. – volume: 35 year: 2021 publication-title: J. Diabetes Complications – volume: 10 year: 2020 publication-title: Clin. Obes. – volume: 12 start-page: 4569 year: 2021 publication-title: Nat. Commun. – volume: 8 year: 2020 publication-title: PeerJ – volume: 109 start-page: 78 year: 2016 end-page: 87 publication-title: Biomaterials – volume: 551 start-page: 251 year: 2017 end-page: 255 publication-title: Nature – volume: 181 start-page: 914 year: 2020 end-page: 921 publication-title: Cell – ident: e_1_2_9_9_2 doi: 10.1038/s41467-021-24824-z – ident: e_1_2_9_3_1 – ident: e_1_2_9_45_2 doi: 10.1016/j.diabres.2020.108347 – ident: e_1_2_9_50_2 doi: 10.1016/j.tranon.2019.06.007 – ident: e_1_2_9_56_2 doi: 10.1007/s00432-018-2796-0 – ident: e_1_2_9_38_1 doi: 10.3390/genes13050910 – year: 2022 ident: e_1_2_9_17_2 publication-title: J. Mass Spectrom. – ident: e_1_2_9_47_1 – ident: e_1_2_9_35_1 doi: 10.1016/0006-291X(75)90361-7 – ident: e_1_2_9_24_2 doi: 10.1038/s41421-020-00241-2 – ident: e_1_2_9_63_1 doi: 10.1021/acsomega.7b01482 – ident: e_1_2_9_15_2 doi: 10.1093/nar/30.5.1124 – ident: e_1_2_9_60_1 – ident: e_1_2_9_27_1 – volume: 10 year: 2022 ident: e_1_2_9_1_1 publication-title: Biomedicine – ident: e_1_2_9_42_2 doi: 10.1016/j.annonc.2020.03.296 – ident: e_1_2_9_8_1 – ident: e_1_2_9_14_2 doi: 10.1021/acs.joc.9b01527 – ident: e_1_2_9_41_1 – year: 2020 ident: e_1_2_9_30_2 publication-title: bioRxiv – ident: e_1_2_9_34_1 doi: 10.1016/j.biomaterials.2016.09.006 – ident: e_1_2_9_25_2 doi: 10.1128/mBio.02131-20 – ident: e_1_2_9_59_1 doi: 10.7717/peerj.10181 – ident: e_1_2_9_39_1 doi: 10.1038/s41586-020-2008-3 – ident: e_1_2_9_11_2 doi: 10.1038/s41421-021-00318-6 – ident: e_1_2_9_52_2 doi: 10.3389/fmolb.2021.692130 – ident: e_1_2_9_43_2 doi: 10.1016/j.ctrv.2020.102041 – ident: e_1_2_9_44_2 doi: 10.1016/j.jdiacomp.2020.107817 – ident: e_1_2_9_10_2 doi: 10.1186/s12920-020-00839-1 – ident: e_1_2_9_58_1 doi: 10.1093/nar/gky341 – ident: e_1_2_9_48_2 doi: 10.1126/sciadv.abd2605 – ident: e_1_2_9_4_2 doi: 10.1016/S1473-3099(22)00143-8 – year: 2020 ident: e_1_2_9_28_2 publication-title: bioRxiv – ident: e_1_2_9_32_2 doi: 10.3390/v13112108 – ident: e_1_2_9_61_2 doi: 10.1038/nature24456 – ident: e_1_2_9_54_1 – year: 2020 ident: e_1_2_9_29_2 publication-title: bioRxiv – ident: e_1_2_9_19_1 – ident: e_1_2_9_13_1 – ident: e_1_2_9_37_1 doi: 10.1128/mBio.01067-21 – volume: 9 start-page: 1442 year: 2021 ident: e_1_2_9_2_1 publication-title: J. Allergy Clin. Immunol. – ident: e_1_2_9_18_1 doi: 10.1007/s00706-022-02896-x – ident: e_1_2_9_49_2 doi: 10.1038/sj.bjc.6606012 – ident: e_1_2_9_64_1 doi: 10.3762/bjoc.15.108 – ident: e_1_2_9_33_1 doi: 10.1038/s41467-019-12504-y – ident: e_1_2_9_6_2 doi: 10.1038/s41590-021-01030-z – ident: e_1_2_9_40_1 doi: 10.1038/nature16998 – ident: e_1_2_9_46_2 doi: 10.1111/cob.12403 – ident: e_1_2_9_5_2 doi: 10.3390/vaccines8040700 – ident: e_1_2_9_21_2 doi: 10.1073/pnas.1323705111 – ident: e_1_2_9_53_1 doi: 10.1186/s12876-022-02160-w – ident: e_1_2_9_16_2 doi: 10.1021/acschembio.0c00735 – ident: e_1_2_9_20_2 doi: 10.1038/s41467-020-18463-z – ident: e_1_2_9_36_1 doi: 10.1016/j.molcel.2017.10.019 – ident: e_1_2_9_57_2 doi: 10.3389/fendo.2018.00396 – ident: e_1_2_9_22_2 doi: 10.1126/science.abc1560 – ident: e_1_2_9_55_2 doi: 10.1038/cr.2014.162 – ident: e_1_2_9_51_2 doi: 10.12659/MSM.913556 – ident: e_1_2_9_23_1 – ident: e_1_2_9_62_2 doi: 10.1038/s41592-019-0550-4 – ident: e_1_2_9_26_1 doi: 10.1038/s41588-021-00903-1 – ident: e_1_2_9_31_2 doi: 10.1016/j.cell.2020.04.011 – ident: e_1_2_9_7_1 doi: 10.1002/gepi.22421 – ident: e_1_2_9_12_2 doi: 10.1186/s40246-021-00306-7 |
SSID | ssj0009631 |
Score | 2.4169495 |
Snippet | SARS‐CoV‐2 causes individualized symptoms. Many reasons have been given. We propose that an individual's epitranscriptomic system could be responsible as well.... SARS-CoV-2 causes individualized symptoms. Many reasons have been given. We propose that an individual's epitranscriptomic system could be responsible as well.... SARS-CoV-2 causes individualized symptoms. Many reasons have been given. We propose that an individual’s epitranscriptomic system could be responsible as well.... |
SourceID | pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | e202300095 |
SubjectTerms | 5-Methylcytosine Adenosine Catalytic activity COVID-19 Diabetes mellitus epitranscriptomics Genomes Humans N6-methyladenosine Replication Ribonucleic acid RNA RNA - genetics RNA modification RNA, Viral - genetics RNA-dependent RNA polymerase SARS-CoV-2 SARS-CoV-2 - genetics Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Viral diseases |
Title | Effects of Epitranscriptomic RNA Modifications on the Catalytic Activity of the SARS‐CoV‐2 Replication Complex |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcbic.202300095 https://www.ncbi.nlm.nih.gov/pubmed/36752976 https://www.proquest.com/docview/2801883960 https://www.proquest.com/docview/2774499019 https://pubmed.ncbi.nlm.nih.gov/PMC10121919 |
Volume | 24 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6hXuACpeWRUpCREJzSJo7zOoaoVYvUHrYU9Rb5FbGiJFV3V6Kc-An8Rn4JM_Ym7VKhSnCJEtl52B6Pv3nkM8CbtpUIFNI0FELkoZBFGxayjENlIkWAQMeOjuHoODs4FR_O0rMbf_F7fojR4UYzw-lrmuBSzXavSUO1mhIFIUJoggmohClhi1DR5Jo_CqXLWVyCwp2c5wNrY8R3V29fXZVuQc3bGZM3kaxbivYfgRwa4TNQvuws5mpHf_-D3_F_WrkOD5c4lVVesB7DPdttwGbVoY3-9Yq9ZS5z1LnkN-B-PewatwmXng55xvqW7V1M57QUOsVEfz-zyXHFjnpD6UneU8j6jiEEZTV5ka7wXazSfj8LegCVnFSTk18_ftb9JzxyhgbD4GZkpMvO7bcncLq_97E-CJf7OoQajfE0VKootM3aEkVDRCpRKEeWS0VRXp63RvEoK62NrIiFRgTI26yUqIiS1PA8Njx5Cmtd39nnwDSiHWFUkpQ2EsIIJWwqTdyWptCJ4iKAcBjXRi9Jz2nvjfPG0zXzhjq4GTs4gHdj_QtP9_HXmtuDmDTLaT9rsAFxgZAziwJ4PRbjCFAURna2X2AdBNyCopFlAM-8VI2vStB84wgQAyhW5G2sQGTgqyXd9LMjBSeeNrS98aHcydMdn9_U7w_r8WrrX256AQ_onEJrcb4Na_PLhX2JCG2uXrlZ-Bu2EzR0 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BOZQLjxZKoICREJzSJo7zOoao1Ra6e9i2iFsUPyJWlKRqdyXKiZ_Ab-SXMGNvUpYKIcElUmLnYXtsf_PINwAvm6ZGoBDHvhAi9UWdNX5W56EvdSAJEKjQ0jGMJ8noRLz9EPfRhPQvjOOHGAxuNDPsek0TnAzSu1esoUrOiIMQMTThhJtwi9J6W61qesUghfJldS5BDk_O0563MeC7q_ev7kvXwOb1mMlfsazdjPbvguyb4WJQPu0s5nJHff2N4fG_2nkP7iyhKiucbN2HG6bdgM2iRTX98yV7xWzwqLXKb8B62SeO24Rzx4h8wbqG7Z3N5rQb2rWJfoBm00nBxp2mCCVnLGRdyxCFspIMSZf4LlYol9KCHkAlR8X06Me372X3Ho-coc7QWxoZLWen5ssDONnfOy5H_jK1g69QH499KbNMmaTJUTpEICOJomR4LcnRy9NGSx4kuTGBEaFQCAJ5k-Q1rkVRrHkaah49hLW2a80jYAoBj9AyinITCKGFFCauddjkOlOR5MIDvx_YSi15zyn9xmnlGJt5RR1cDR3sweuh_plj_Phjze1eTqrlzL-osAFhhqgzCTx4MRTjCJAjpm5Nt8A6iLkFOSRzD7acWA2vilCD44gRPchWBG6oQHzgqyXt7KPlBSeqNlS_8aHcCtRfPr8q3xyUw9njf7npOayPjseH1eHB5N0TuE3XydMWptuwNj9fmKcI2ObymZ2SPwHeCDiP |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LbtQwFL2CIkE3PFoooQWMhGCVNnGc1zKkHbVAR2hKUXdR_IgYtU1G7YxEWfEJ_Ua-hHudSdqhQkiwiZTYedg-ts-91zkGeF1VJRKFMHSFELEryqRykzL1Xak9SYRA-VaOYX8Y7R6K90fh0bW_-Ft9iN7hRj3DjtfUwSe62roSDVVyTBKESKGJJtyGOyLyEsL19uhKQArhZU0uQfFOzuNOttHjW4v3L05LN7jmzSWT16msnYsGD6DsStEuQTnenE3lpvr-m8Dj_xTzIdyfE1WWtch6BLdMvQKrWY1G-ukFe8Ps0lHrk1-Be3m3bdwqnLV6yOesqdjOZDyludCOTPT7MxsNM7bfaFqf1LoKWVMz5KAsJzfSBb6LZard0IIeQCkH2ejg54_LvPmCR87QYuj8jIwGsxPz7TEcDnY-57vufGMHV6E1HrpSJokyUZUiNoQnA4lAMryUFOblcaUl96LUGM8IXyikgLyK0hJHoiDUPPY1D57AUt3U5ikwhXRHaBkEqfGE0EIKE5bar1KdqEBy4YDbtWuh5qrntPnGSdHqNfOCKrjoK9iBt33-Sav38cecGx1Minm_Py-wAH6CnDPyHHjVJ2MLUBimrE0zwzzIuAWFI1MH1lpU9a8K0H7jyBAdSBbw1mcgNfDFlHr81aqCk1AbGt_4UG7x9JfPL_J3e3l_9uxfbnoJdz9tD4qPe8MP67BMlynM5scbsDQ9m5nnyNam8oXtkL8AJ9Y3Rw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+Epitranscriptomic+RNA+Modifications+on+the+Catalytic+Activity+of+the+SARS%E2%80%90CoV%E2%80%902+Replication+Complex&rft.jtitle=Chembiochem+%3A+a+European+journal+of+chemical+biology&rft.au=Apostle%2C+Alexander&rft.au=Yin%2C+Yipeng&rft.au=Chillar%2C+Komal&rft.au=Eriyagama%2C+Adikari+M.+D.+N.&rft.date=2023-04-17&rft.issn=1439-4227&rft.eissn=1439-7633&rft.volume=24&rft.issue=8&rft_id=info:doi/10.1002%2Fcbic.202300095&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_cbic_202300095 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1439-4227&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1439-4227&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1439-4227&client=summon |